WILMINGTON, Del., Jan. 11, 2016 /PRNewswire/ -- Lucerne Biosciences, LLC announced today that it has completed a sourcing investigation into the U.S. Patent Trial & Appeal Board’s invalidation of U.S. Patent 8,318,813 titled Method of Treating Binge Eating Disorder and is now beginning an accelerated multi-party public expansion phase to introduce its counter-intelligence technology to the American and global public-at-large. The company’s ‘813 Patent was invalidated on June 4, 2015 based on an Inter Partes Review petition filed by Shire Development LLC on May 9, 2014, supported by law firm Frommer, Lawrence & Haug, LLP and Eating Disorder Expert Timothy Brewerton, M.D. Prior investigation by the company and its collaborators determined Shire’s IPR, and the Brewerton Declaration on which it was based, advanced a platform of anti-competitive trade practice, the motivations of which were initially unclear.
The results of the sourcing investigation are publicly available for download in a 1645-page PDF document titled “Are You Ready for the Imminent Confluence of Networks (Final Resolution)?,” including approximately 4000 hyperlinked references and extensive electronic and representational profiling using counter-intelligence techniques such as temporally-weighted profiling and sequential expanded analysis (at: https://app.box.com/s/89bnw8lk5htji6an53oezeg7ei2ham2u). On January 6, 2016, Lucerne Biosciences provided results of the sourcing investigation to Shire executives, including CEO Dr. Flemming Ornskov, Frommer, Lawrence & Haug attorneys Ed Haug and Sandra Kuzmich, Dr. Timothy Brewerton (to whom the letter was addressed) and various other attorneys involved in the matter. This was in expectation of Lucerne Biosciences’ accelerated public expansion phase designed to bring broad public attention to what occurred through the company’s counter-intelligence technology that uses publicly available information on the Internet to establish “layered composite profiling” at the person, corporate, governmental and/or electronic levels “to explain the story for any reasonable person to understand” (1-6-2016 communication available in PDF at: https://app.box.com/s/nb4nsf0h39ce9puk6f16w2j6h45ecffb).
Lucerne Biosciences’ Manager Louis Sanfilippo stated, “This is an extraordinary story that you wouldn’t believe possible until you see the evidence. Then it becomes very obvious it’s real and also what it’s all about, namely, the Internet and how its infrastructure was built at the level of name servers, IPv4 address allocation and Autonomous System Numbers, among other things. The sourcing investigation originally stemmed from trying to explain an unusually high degree of representational exploitation and deception in the IPR proceeding, more than you would expect from the kinds of professionals involved. This included the Patent Trial & Appeal Board which showcased a record 40-75% misrepresentation rate, depending on how you count, in identifying the owner of the ‘813 Patent for its face-page represented Orders during Lucerne’s slice of the proceeding. Additional USPTO representational problems, like Director Ms. Lee’s misrepresentation of a patent number in its Certificate of Correction for a Yale University ‘sensor network patent’ whose claims could be exploited to advance the very deception platform later seen in the IPR proceeding, drew high suspicion on account of its timing just before the first ‘813 patent owner LCS Group, LLC filed its preliminary response. That’s what opened the door to further investigation.”
The sourcing investigation identified two known intelligence tactics that were repeatedly and extensively exploited across multiple-parties in a highly coordinated tactical manner, including by the PTAB. One such tactic is called “disruptive technology,” historically associated in the public space with the US National Security Agency (NSA). The other, called “onion routing,” is a tactic used to securely move data through communication networks and has its historical roots in the Naval Research Laboratory (NRL). Sanfilippo added, “The composite profile strongly supports a massively scaled ‘invite-only, collaboratively-based Virtual Private Network (VPN)’ designed to bring attention to the Internet among a trusted network while, at the same time, high-tech defense contractors and even US intelligence agencies could electronically exploit the platform to develop new surveillance, data-gathering/interception and secure overlay communication technologies. Things appear to have gotten derailed when Shire merged the disruptively represented VPN platform with a disruptively represented IPR petition, in effect seeking to leverage a fraudulent IPR proceeding against the patent’s first owner LCS Group while at the same time in a confidentiality disclosure agreement with LCS Group to acquire rights to the patent. Shire probably thought it would end well and quietly if it could exert enough muscle on all sides, including from the USPTO and supporters of the VPN. Remarkably, the investigation into Shire’s conduct strongly supports that this massively-scaled VPN was a secondary platform, the first of which was originally designed to build the Internet’s infrastructure through highly-coordinated private communications among a ‘trusted network.’ An organization called the Intelligence Science Board, chartered in August 2002, drew high suspicion in the sourcing investigation because it stood in-between both platforms on multiple levels, including its connection to shared contacts involving ‘me’ .”
The sourcing investigation includes government entities like the NSF, CIA, NSA, DoD, Commerce, and DoE, as well as high tech academic centers like MIT and USC’s Information Sciences Institute, and corporations that were central to the development of the Internet like BBN Corporation (as formerly known 1995-2000), IBM, AT&T, GTE, Bechtel, and Level 3 Communications, across their various corporate forms. Raytheon Company, a defense contractor whose former headquarters sits amidst the campus of Shire’s current Lexington, Mass. global center, is extensively investigated for its potential role in advancing the technology. “It’s a big story and seems to get bigger at every turn,” said Sanfilippo, “and at the center of the onion, you might say, is a series of companies called Genuity Inc. That may be the most remarkable feature of this secret story that’s been concealed from the American and global public-at-large.”
About Lucerne Biosciences, LLC
Lucerne Biosciences is a counter-intelligence technology development company involved in deception detection methodology, resolution management and electronic Internet Protocol profiling based on publicly available information from the Internet. The company’s policy is broad public distribution of its technology once it has been determined effective and safe for broad public application. Communications can be made to lucernebio@lucernebio.com.
Additional, Related Information
The Patent ‘813 Story, Part II, Version 2 (updated January 11, 2016) at: https://app.box.com/s/f4gcdmbmxhpdncu9yn4x1oqq4bsmwfa6
PTAB Invalidates Lucerne Biosciences’ ‘813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate (June 13, 2015) at: http://www.prnewswire.com/news-releases/ptab-invalidates-lucerne-biosciences-813-patent-for-the-treatment-of-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300098752.html
Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate (March 6, 2015) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-announces-publication-of-claimed-methods-for-treating-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300046271.html
LCS Group Announces Exclusive License from Lucerne Biosciences to Commercialize ‘813 Patent and ‘249 Application through Shire’s Marketing of Lisdexamfetamine Dimesylate for Binge Eating Disorder (May 13, 2015) at: http://www.prnewswire.com/news-releases/lcs-group-announces-exclusive-license-from-lucerne-biosciences-to-commercialize-813-patent-and-249-application-through-shires-marketing-of-lisdexamfetamine-dimesylate-for-binge-eating-disorder-300083124.html
LCS Therapeutics and Lucerne Biosciences to Commercialize ‘813 Patent for Lisdexamfetamine Dimesylate in the Treatment of Binge Eating Disorder (December 26, 2014) at: http://www.prnewswire.com/news-releases/lcs-therapeutics-and-lucerne-biosciences-to-commercialize-813-patent-for-lisdexamfetamine-dimesylate-in-the-treatment-of-binge-eating-disorder-300013986.html
Media Contact:
Louis Sanfilippo, MD
203-521-1143
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-begins-accelerated-multi-party-public-expansion-phase-of-its-counter-intelligence-technology-300202785.html
SOURCE Lucerne Biosciences, LLC
